Somaxon’s Silenor Joins Sleep Aid Market
According to Richard Pascoe, president and CEO of Somaxon, Silenor the first sleep aid that hasn’t been deemed a controlled substance.
vanda pharmaceuticals
FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.
FDA Approves Fanapt for Schizophrenia Patients
Maryland-based Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration has approved Fanapt (otherwise known as iloperidone) for the acute treatment of adult patients with schizophrenia.